We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.
- Authors
Rögnvaldsson, Sæmundur; Love, Thorvardur Jon; Thorsteinsdottir, Sigrun; Reed, Elín Ruth; Óskarsson, Jón Þórir; Pétursdóttir, Íris; Sigurðardóttir, Guðrún Ásta; Viðarsson, Brynjar; Önundarson, Páll Torfi; Agnarsson, Bjarni A.; Sigurðardóttir, Margrét; Þorsteinsdóttir, Ingunn; Ólafsson, Ísleifur; Þórðardóttir, Ásdís Rósa; Eyþórsson, Elías; Jónsson, Ásbjörn; Björnsson, Andri S.; Gunnarsson, Gunnar Þór; Pálsson, Runólfur; Indriðason, Ólafur Skúli
- Abstract
Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population-based screening study for MGUS including a randomized trial of follow-up strategies. Icelandic residents born before 1976 were offered participation. Blood samples are collected alongside blood sampling in the Icelandic healthcare system. Participants with MGUS are randomized to three study arms. Arm 1 is not contacted, arm 2 follows current guidelines, and arm 3 follows a more intensive strategy. Participants who progress are offered early treatment. Samples are collected longitudinally from arms 2 and 3 for the study biobank. All participants repeatedly answer questionnaires on various exposures and outcomes including quality of life and psychiatric health. National registries on health are cross-linked to all participants. Of the 148,704 individuals in the target population, 80 759 (54.3%) provided informed consent for participation. With a very high participation rate, the data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of screening. The study can lead to a paradigm shift in MM therapy towards screening and early therapy.
- Subjects
MULTIPLE myeloma; MONOCLONAL gammopathies; BLOOD sampling; FOLLOW-up studies (Medicine); RANDOMIZED controlled trials
- Publication
Blood Cancer Journal, 2021, Vol 11, Issue 5, p1
- ISSN
2044-5385
- Publication type
Article
- DOI
10.1038/s41408-021-00480-w